Signal transducer and activator of transcription 5b promotes mucosal tolerance in pediatric Crohn's disease and murine colitis

American Journal of Pathology

Volumn 169, Issue 6, 2006, Pages 1999-2013

  Han, Xiaonan ^a   Osuntokun, Bankole ^a   Benight, Nancy ^a   Loesch, Kimberly ^b   Frank, Stuart J ^b,c,d   Denson, Lee A ^a,e  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c University of Alabama at Birmingham   (United States)

^d BIRMINGHAM VA MEDICAL CENTER   (United States)

^e NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; ROSIGLITAZONE; STAT5 PROTEIN; TRINITROBENZENESULFONIC ACID; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; CARRIER PROTEIN; SOMATOTROPIN BINDING PROTEIN; SOMATOTROPIN-BINDING PROTEIN; STAT5B PROTEIN, HUMAN;

ADOLESCENT; ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHILD; COLON BIOPSY; CONTROLLED STUDY; CROHN DISEASE; DISEASE SEVERITY; DOWN REGULATION; EPITHELIUM CELL; HUMAN; HUMAN TISSUE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; WILD TYPE; ANIMAL; C57BL MOUSE; COLITIS; COLON; CYTOLOGY; FEMALE; GENETIC PREDISPOSITION; GENETICS; INTESTINE MUCOSA; MALE; METABOLISM; MUCOSA; PATHOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; CARRIER PROTEINS; CHILD; COLITIS; COLON; CROHN DISEASE; EPITHELIAL CELLS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; HYPOGLYCEMIC AGENTS; INTESTINAL MUCOSA; MALE; MICE; MICE, INBRED C57BL; MUCOUS MEMBRANE; NF-KAPPA B; PPAR GAMMA; SIGNAL TRANSDUCTION; STAT5 TRANSCRIPTION FACTOR; THIAZOLIDINEDIONES; TRINITROBENZENESULFONIC ACID;

EID: 35648986090     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.2353/ajpath.2006.060186     Document Type: Article

References (54)

1. Bouma G, Strober W: The immunological and genetic basis of inflammatory bowel disease. Nat Rev Immunol 2003, 3:521-533
2. Neurath MF, Pettersson S, Meyer zum Buschenfelde KH, Strober W: Local administration of antisense phosphorothioate oligonucleotides to the p65 subunit of NF-kappa B abrogates established experimental colitis in mice. Nat Med 1996, 2:998-1004
3. Costello CM, Mah N, Hasler R, Rosenstiel P, Waetzig GH, Hahn A, Lu T, Gurbuz Y, Nikolaus S, Albrecht M, Hampe J, Lucius R, Kloppel G, Eickhoff H, Lehrach H, Lengauer T, Schreiber S: Dissection of the inflammatory bowel disease transcriptome using genome-wide cDNA microarrays. PLoS Med 2005, 2:e199
4. Snow JW, Abraham N, Ma MC, Herndier BG, Pastuszak AW, Goldsmith MA: Loss of tolerance and autoimmunity affecting multiple organs in STAT5A/5B-deficient mice. J Immunol 2003, 171:5042-5050
5. Davey HW, Park SH, Grattan DR, McLachlan MJ, Waxman DJ: STAT5b-deficient mice are growth hormone pulse-resistant. Role of STAT5b in sex-specific liver p450 expression. J Biol Chem 1999, 274:35331-35336
6. Davey HW, Wilkins RJ, Waxman DJ: STAT5 signaling in sexually dimorphic gene expression and growth patterns. Am J Hum Genet 1999, 65:959-965
7. Davey HW, Xie T, McLachlan MJ, Wilkins RJ, Waxman DJ, Grattan DR: STAT5b is required for GH-induced liver IGF-I gene expression. Endocrinology 2001, 142:3836-3841
8. Teglund S, McKay C, Schuetz E, van Deursen JM, Stravopodis D, Wang D, Brown M, Bodner S, Grosveld G, Ihle JN: Stat5a and Stat5b proteins have essential and nonessential, or redundant, roles in cytokine responses. Cell 1998, 93:841-850
9. Chen K, Nezu R, Inoue M, Wasa M, Iiboshi Y, Fukuzawa M, Kamata S, Takagi Y, Okada A: Beneficial effects of growth hormone combined with parenteral nutrition in the management of inflammatory bowel disease: an experimental study. Surgery 1997, 121:212-218
10. Han X, Sosnowska D, Bonkowski E, Denson L: Growth hormone reduces STAT3 activation and improves disease activity in murine colitis. Gastroenterology 2005, 129:185-203
11. Kara E, Sungurtekin H, Sungurtekin U, Alkanat M, Ilkgul O: The effect of recombinant human growth hormone (rhGH) on trinitrobenzene sulfonic acid-induced colitis in rats: an experimental study. Inflamm Bowel Dis 2004, 10:112-115
12. Williams KL, Fuller CR, Dieleman LA, DaCosta CM, Haldeman KM, Sartor RB, Lund PK: Enhanced survival and mucosal repair after dextran sodium sulfate- induced colitis in transgenic mice that overexpress growth hormone. Gastroenterology 2001, 120:925-937
13. Theiss AL, Fuller CR, Simmons JG, Liu B, Sartor RB, Lund PK: Growth hormone reduces the severity of fibrosis associated with chronic intestinal inflammation. Gastroenterology 2005, 129:204-219
14. Slonim AE, Bulone L, Damore MB, Goldberg T, Wingertzahn MA, McKinley MJ: A preliminary study of growth hormone therapy for Crohn's disease. N Engl J Med 2000, 342:1633-1637
15. Desreumaux P, Dubuquoy L, Nutten S, Peuchmaur M, Englaro W, Schoonjans K, Derijard B, Desvergne B, Wahli W, Chambon P, Leibowitz MD, Colombel JF, Auwerx J: Attenuation of colon inflammation through activators of the retinoid X receptor (RXR)/peroxisome proliferator-activated receptor gamma (PPARgamma) heterodimer. A basis for new therapeutic strategies. J Exp Med 2001, 193:827-838
16. Kelly D, Campbell JI, King TP, Grant G, Jansson EA, Coutts AG, Pettersson S, Conway S: Commensal anaerobic gut bacteria attenuate inflammation by regulating nuclear-cytoplasmic shuttling of PPAR-gamma and RelA. Nat Immunol 2004, 5:104-112
17. Katayama K, Wada K, Nakajima A, Mizuguchi H, Hayakawa T, Nakagawa S, Kadowaki T, Nagai R, Kamisaki Y, Blumberg RS, Mayumi T: A novel PPAR gamma gene therapy to control inflammation associated with inflammatory bowel disease in a murine model. Gastroenterology 2003, 124:1315-1324
18. Lytle C, Tod TJ, Vo KT, Lee JW, Atkinson RD, Straus DS: The peroxisome proliferator-activated receptor gamma ligand rosiglitazone delays the onset of inflammatory bowel disease in mice with interleukin 10 deficiency. Inflamm Bowel Dis 2005, 11:231-243
19. Schaefer KL, Denevich S, Ma C, Cooley SR, Nakajima A, Wada K, Schlezinger J, Sherr D, Saubermann LJ: Intestinal antiinflammatory effects of thiazolidenedione peroxisome proliferator-activated receptor-gamma ligands on T helper type 1 chemokine regulation include nontranscriptional control mechanisms. Inflamm Bowel Dis 2005, 11:244-252
20. Lewis JD, Lichtenstein GR, Stein RB, Deren JJ, Judge TA, Fogt F, Furth EE, Demissie EJ, Hurd LB, Su CG, Keilbaugh SA, Lazar MA, Wu GD: An open-label trial of the PPAR-gamma ligand rosiglitazone for active ulcerative colitis. Am J Gastroenterol 2001, 96:3323-3328
21. Su CG, Wen X, Bailey ST, Jiang W, Rangwala SM, Keilbaugh SA, Flanigan A, Murthy S, Lazar MA, Wu GD: A novel therapy for colitis utilizing PPAR-gamma ligands to inhibit the epithelial inflammatory response. J Clin Invest 1999, 104:383-389
22. Dubuquoy L, Jansson EA, Deeb S, Rakotobe S, Karoui M, Colombel JF, Auwerx J, Pettersson S, Desreumaux P: Impaired expression of peroxisome proliferator-activated receptor gamma in ulcerative colitis. Gastroenterology 2003, 124:1265-1276
23. Rousseaux C, Lefebvre B, Dubuquoy L, Lefebvre P, Romano O, Auwerx J, Metzger D, Wahli W, Desvergne B, Naccari GC, Chavatte P, Farce A, Bulois P, Cortot A, Colombel JF, Desreumaux P: Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-gamma. J Exp Med 2005, 201:1205-1215
24. Saubermann LJ, Nakajima A, Wada K, Zhao S, Terauchi Y, Kadowaki T, Aburatani H, Matsuhashi N, Nagai R, Blumberg RS: Peroxisome proliferator- activated receptor gamma agonist ligands stimulate a Th2 cytokine response and prevent acute colitis. Inflamm Bowel Dis 2002, 8:330-339
25. Meirhaeghe A, Fajas L, Gouilleux F, Cottel D, Helbecque N, Auwerx J, Amouyel P: A functional polymorphism in a STAT5B site of the human PPAR gamma 3 gene promoter affects height and lipid metabolism in a French population. Arterioscler Thromb Vasc Biol 2003, 23:289-294
26. Cowan JW, Wang X, Guan R, He K, Jiang J, Baumann G, Black RA, Wolfe MS, Frank SJ: Growth hormone receptor is a target for presenilin-dependent gamma-secretase cleavage. J Biol Chem 2005, 280:19331-19342
27. D'Haens GR, Geboes K, Peeters M, Baert F, Penninckx F, Rutgeerts P: Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum. Gastroenterology 1998, 114:262-267
28. D'haens G, Van Deventer S, Van Hogezand R, Chalmers D, Kothe C, Baert F, Braakman T, Schaible T, Geboes K, Rutgeerts P: Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: a European multicenter trial. Gastroenterology 1999, 116:1029-1034
29. Chow JY, Carlstrom K, Barrett KE: Growth hormone reduces chloride secretion in human colonic epithelial cells via EGF receptor and extracellular regulated kinase. Gastroenterology 2003, 125:1114-1124
30. DiFedele LM, He J, Bonkowski EL, Han X, Held MA, Bohan A, Menon RK, Denson LA: Tumor necrosis factor alpha blockade restores growth hormone signaling in murine colitis. Gastroenterology 2005, 128:1278-1291
31. Elson CO, Beagley KW, Sharmanov AT, Fujihashi K, Kiyono H, Tennyson GS, Cong Y, Black CA, Ridwan BW, McGhee JR: Hapten-induced model of murine inflammatory bowel disease: mucosa immune responses and protection by tolerance. J Immunol 1996, 157:2174-2185
32. Neurath MF, Fuss I, Kelsall BL, Stuber E, Strober W: Antibodies to interleukin 12 abrogate established experimental colitis in mice. J Exp Med 1995, 182:1281-1290
33. Becker C, Fantini MC, Schramm C, Lehr HA, Wirtz S, Nikolaev A, Burg J, Strand S, Kiesslich R, Huber S, Ito H, Nishimoto N, Yoshizaki K, Kishimoto T, Galle PR, Blessing M, Rose-John S, Neurath MF: TGF-beta suppresses tumor progression in Th2 colitis and associated colon cancer by inhibition of IL-6 trans-signaling. Immunity 2004, 21:491-501
34. Kola B, Korbonits M, Diaz-Cano S, Kaltsas G, Morris DG, Jordan S, Metherell L, Powell M, Czirjak S, Arnaldi G, Bustin S, Boscaro M, Mantero F, Grossman AB: Reduced expression of the growth hormone and type 1 insulin-like growth factor receptors in human somatotroph tumours and an analysis of possible mutations of the growth hormone receptor. Clin Endocrinol (Oxf) 2003, 59:328-338
35. Woelfle J, Chia DJ, Rotwein P: Mechanisms of growth hormone (GH) action: identification of conserved Stat5 binding sites that mediate GH-induced insulin-like growth factor-I gene activation. J Biol Chem 2003, 278:51261-51266
36. Han X, Fink MP, Uchiyama T, Yang R, Delude RL: Increased iNOS activity is essential for pulmonary epithelial tight junction dysfunction in endotoxemic mice. Am J Physiol Lung Cell Mol Physiol 2004, 286:L259-L267
37. Kugathasan S, Judd RH, Hoffmann RG, Heikenen J, Telega G, Khan F, Weisdorf-Schindele S, San Pablo Jr W, Perrault J, Park R, Yaffe M, Brown C, Rivera-Bennett MT, Halabi I, Martinez A, Blank E, Werlin SL, Rudolph CD, Binion DG: Epidemiologic and clinical characteristics of children with newly diagnosed inflammatory bowel disease in Wisconsin: a statewide population-based study. J Pediatr 2003, 143:525-531
38. Denson LA, Menon RK, Shaufl A, Bajwa HS, Williams CR, Karpen SJ: TNF-alpha downregulates murine hepatic growth hormone receptor expression by inhibiting Sp1 and Sp3 binding. J Clin Invest 2001, 107:1451-1458
39. Rowland JE, Lichanska AM, Kerr LM, White M, d'Aniello EM, Maher SL, Brown R, Teasdale RD, Noakes PG, Waters MJ: In vivo analysis of growth hormone receptor signaling domains and their associated transcripts. Mol Cell Biol 2005, 25:66-77
40. Lobie PE, Breipohl W, Waters MJ: Growth hormone receptor expression in the rat gastrointestinal tract. Endocrinology 1990, 126:299-306
41. Lefebvre M, Paulweber B, Fajas L, Woods J, McCrary C, Colombel JF, Najib J, Fruchart JC, Datz C, Vidal H, Desreumaux P, Auwerx J: Peroxisome proliferator-activated receptor gamma is induced during differentiation of colon epithelium cells. J Endocrinol 1999, 162:331-340
42. Löwenberg M, Scheffer M, Verhaar A, Peppelenbosch M, Hommes D: A role for STAT5 in steroid-resistant UC? Inflamm Bowel Dis 2006, 12:665
43. Han X, Benight N, Osuntokun B, Loesch K, Frank S, Denson L: Tumour necrosis factor {alpha} blockade induces an anti-inflammatory growth hormone signalling pathway in experimental colitis. Gut 2006, (in press)
44. Shipley JM, Waxman DJ: Simultaneous, bidirectional inhibitory crosstalk between PPAR and STAT5b. Toxicol Appl Pharmacol 2004, 199:275-284
45. Rieusset J, Seydoux J, Anghel SI, Escher P, Michalik L, Soon Tan N, Metzger D, Chambon P, Wahli W, Desvergne B: Altered growth in male peroxisome proliferator-activated receptor gamma (PPARgamma) heterozygous mice: involvement of PPARgamma in a negative feedback regulation of growth hormone action. Mol Endocrinol 2004, 18:2363-2377
46. Masternak MM, Al-Regaiey KA, Del Rosario Lim MM, Bonkowski MS, Panici JA, Przybylski GK, Bartke A: Caloric restriction results in decreased expression of peroxisome proliferator-activated receptor superfamily in muscle of normal and long-lived growth hormone receptor/binding protein knockout mice. J Gerontol A Biol Sci Med Sci 2005, 60:1238-1245
47. Bogazzi F, Ultimieri F, Raggi F, Costa A, Gasperi M, Cecconi E, Mosca F, Bartalena L, Martino E: Peroxisome proliferator activated receptor gamma expression is reduced in the colonic mucosa of acromegalic patients. J Clin Endocrinol Metab 2002, 87:2403-2406
48. Sánchez-Hidalgo M, Martin AR, Villegas I, Alarcon De La Lastra C: Rosiglitazone, an agonist of peroxisome proliferator-activated receptor gamma, reduces chronic colonic inflammation in rats. Biochem Pharmacol 2005, 69:1733-1744
49. Adachi M, Kurotani R, Morimura K, Shah Y, Sanford M, Madison BB, Gumucio DL, Marin HE, Peters JM, Young HA, Gonzalez FJ: PPAR{gamma} in colonic epithelial cells protects against experimental inflammatory bowel disease. Gut 2006, 55:1104-1113
50. Kim SC, Tonkonogy SL, Albright CA, Tsang J, Balish EJ, Braun J, Huycke MM, Sartor RB: Variable phenotypes of enterocolitis in interleukin 10-deficient mice monoassociated with two different commensal bacteria. Gastroenterology 2005, 128:891-906
51. Swidsinski A, Loening-Baucke V, Lochs H, Hale LP: Spatial organization of bacterial flora in normal and inflamed intestine: a fluorescence in situ hybridization study in mice. World J Gastroenterol 2005, 11:1131-1140
52. Swidsinski A, Weber J, Loening-Baucke V, Hale LP, Lochs H: Spatial organization and composition of the mucosal flora in patients with inflammatory bowel disease. J Clin Microbiol 2005, 43:3380-3389
53. Lehtonen A, Matikainen S, Miettinen M, Julkunen I: Granulocyte-macrophage colony-stimulating factor (GM-CSF)-induced STAT5 activation and target-gene expression during human monocyte/macrophage differentiation. J Leukoc Biol 2002, 71:511-519
54. Korzenik JR, Dieckgraefe BK, Valentine JF, Hausman DF, Gilbert MJ: Sargramostim for active Crohn's disease. N Engl J Med 2005, 352:2193-2201